(E)-3-[2-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-acrylic acid methyl ester | 39099-98-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-[2-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-acrylic acid methyl ester
• 英文别名: Cinamolol；methyl (E)-3-[2-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]prop-2-enoate
• CAS: 39099-98-4
• 化学式: C₁₆H₂₃NO₄
• 分子量: 293.363
• InChiKey: LWRSDAUWAOJRPA-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2922509090

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• [EN] CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR<br/>[FR] MODULATEURS CYCLOPROPYLÉS DU RÉCEPTEUR P2Y12
  申请人：AUSPEX PHARMACEUTICALS INC

  公开号：WO2011017108A2

  公开（公告）日：2011-02-10

  The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及新的环丙基P2Y12受体调节剂，其制药组合物以及使用方法。
• CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR
  申请人：Auspex Pharmaceuticals, Inc.

  公开号：US20160193212A1

  公开（公告）日：2016-07-07

  The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及P2Y12受体活性的新环丙基调节剂，其制药组合物以及使用方法。
• DEUTERATED DERIVATIVES OF TICAGRELOR FOR MEDICAL USE
  申请人：Auspex Pharmaceuticals, Inc.

  公开号：EP3135675A1

  公开（公告）日：2017-03-01

  The present invention relates to deuterated compounds having a modulatory activity at the P2Y12 receptor for use in the treatment of myocardial infarction, stroke or acute coronary syndrome.

  本发明涉及具有调节P2Y12受体活性的氘代化合物，用于治疗心肌梗死、中风或急性冠状动脉综合征。
• Pharmaceutical composition for treatment of diabetic complications
  申请人：Vlife Sciences Technologies Pvt Ltd.

  公开号：EP2444077A1

  公开（公告）日：2012-04-25

  A method for treating diabetic complications by administration of a beta-blocker is disclosed. Diabetic complications arise from diabetes and have few or no existing treatment options. The present invention describes the use of a beta-blocker in the treatment of a diabetic. The present invention also describes the inhibition of aldose reductase, one of the chief causative factors of diabetic complications. Also provided are methods of diabetic wound healing. Compositions for treating diabetic complications, such as diabetic wounds, are disclosed. The present invention includes employing a topical formulation of a beta-blocker, having substantially no antibacterial activity, to improve the process of diabetic wound healing. The present invention also involves increasing the rate of collagen accumulation of the healing epithelialized tissue in the wound of a diabetic individual.

  本文公开了一种通过使用β-受体阻滞剂治疗糖尿病并发症的方法。糖尿病并发症由糖尿病引起，现有的治疗方法很少或根本没有。本发明描述了使用β-受体阻滞剂治疗糖尿病的方法。本发明还描述了对醛糖还原酶的抑制，醛糖还原酶是糖尿病并发症的主要致病因素之一。本发明还提供了糖尿病伤口愈合的方法。本发明公开了用于治疗糖尿病并发症（如糖尿病伤口）的组合物。本发明包括采用一种基本上没有抗菌活性的β-受体阻滞剂的局部制剂来改善糖尿病伤口的愈合过程。本发明还包括提高糖尿病患者伤口愈合上皮组织的胶原蛋白累积率。